BUY
Stryker Corp.

They reported top and bottom line growth and organic growth was better than expected. He's bullish about medical devices, given the Covid-induced backlog in surgeries.

biotechnology / pharmaceutical
TOP PICK
Stryker Corp.

Medical device business very strong - high growth area. 
Healthcare sector demand not slowing down.
Aging baby boomer population will require further healthcare.
Need for increased healthcare tech. 

biotechnology / pharmaceutical
TOP PICK
Stryker Corp.

It makes artificial joints and all kinds of specialized medical equipment. It is focused on many areas including hips, knees, ankles, etc. He especially likes the robotic assisted surgery component.     Buy 16  Hold 12  Sell 2

biotechnology / pharmaceutical
PAST TOP PICK
Stryker Corp.
(A Top Pick Mar 16/22, Up 0.1%)

Fell a lot through Covid decline in elective surgeries. Great place to be over the long term. Aging demographics in its favour.

biotechnology / pharmaceutical
BUY
Stryker Corp.

They make artificial hips and knees--a major growth area as the population ages. It pays a minor dividend, is profitable and performance has been strong over 5 years, up 63%. Great long term, given demographics.

biotechnology / pharmaceutical
DON'T BUY
Stryker Corp.

Joint replacements and instrumentation business. Has come back in the latest rally. Good operators, but struggle for space in the operating room. Until that resolves, he'd shy away.

biotechnology / pharmaceutical
PAST TOP PICK
Stryker Corp.
(A Top Pick Mar 16/22, Down 2%) Great business. Backlog in elective surgeries due to Covid will lead to good earnings growth going forward. Good growth internationally. Demographic play. Loyal customer base. Great medical device story.
biotechnology / pharmaceutical
DON'T BUY
Stryker Corp.
SYK vs. ISRG ISRG reported last night, market not too happy, but this is short term. At 50x PE, ISRG is expensive on any traditional valuation, yet has no real competition in robotic surgery market. ISRG has a great franchise and platform, and will grow earnings over next decade 200-300%. Because SYK is in hips and knees, it's not in direct competition. SYK's space is more competitive, but also has much lower valuation. With Covid shortages ending, SYK could see some upside next 3-4 months.
biotechnology / pharmaceutical
PAST TOP PICK
Stryker Corp.
(A Top Pick Nov 02/21, Down 19%) Good growth internationally. Demand increasing with aging population. Great balance sheet, opportunity to make acquisitions. Trades at 22x. Pandemic backlog of elective surgeries offsets inflationary costs. Supply chain difficulties persist. He'd buy here. Yield is 1.4%.
biotechnology / pharmaceutical
HOLD
Stryker Corp.
Medical supply companies impacted by Covid-19, staffing shortages and inflation. Need for healthcare services not going away. Likes business area, but not investing in Stryker. Other companies with better prospects.
biotechnology / pharmaceutical
BUY
Stryker Corp.
Their valuation has declined. Their devices are used in revenue-generating procedures at hospitals, which is safe, even as the economy slows. Good outlook.
biotechnology / pharmaceutical
PAST TOP PICK
Stryker Corp.
(A Top Pick Aug 24/21, Down 23%) It is a medical device company and had a tough time over Covid. Now there is a big backlog in elective surgeries so much more of its products will be needed. 71% of business is from the U.S. where there is lots of room to grow globally. Also doctors doing the surgeries tend to stay with the same products. Lots of free cash flow.
biotechnology / pharmaceutical
BUY
Stryker Corp.
They make medical devices. They bought a medical company focused on hands. Again demographics will increase demand for knee and hip replacements. Also, doctors seldom change device-makers, so they will stick with Stryker. They have little presence outside the U.S. so there are opportunities for growth there. Also, there's a backlog in elective surgeries.
biotechnology / pharmaceutical
PAST TOP PICK
Stryker Corp.
(A Top Pick May 12/21, Down 4%) Elective surgeries shut down due to Covid, so now there's a backlog. Supply chain issues. Employment issues. They can get through these headwinds. Acquisition and integration going well. Digitization being integrated into services, including valuable patient data.
biotechnology / pharmaceutical
HOLD
Stryker Corp.
Robotic-assisted surgery has been a large growth area. Multiple compressed significantly. Elective surgeries accelerating, a positive for the business. Shipping and specialty metal constraints are priced in. Fairly priced. Hold through volatility. Quality company, well run. Look at ROE and ROE growth. Aim for a PE multiple of 21x.
biotechnology / pharmaceutical
Showing 1 to 15 of 132 entries

Stryker Corp.(SYK-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 9

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 13

Stockchase rating for Stryker Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Stryker Corp.(SYK-N) Frequently Asked Questions

What is Stryker Corp. stock symbol?

Stryker Corp. is a American stock, trading under the symbol SYK-N on the New York Stock Exchange (SYK). It is usually referred to as NYSE:SYK or SYK-N

Is Stryker Corp. a buy or a sell?

In the last year, 13 stock analysts published opinions about SYK-N. 9 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Stryker Corp..

Is Stryker Corp. a good investment or a top pick?

Stryker Corp. was recommended as a Top Pick by on . Read the latest stock experts ratings for Stryker Corp..

Why is Stryker Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Stryker Corp. worth watching?

13 stock analysts on Stockchase covered Stryker Corp. In the last year. It is a trending stock that is worth watching.

What is Stryker Corp. stock price?

On 2023-05-31, Stryker Corp. (SYK-N) stock closed at a price of $275.73.